Abstract Aim To provide an insight into our current understanding in the genomics of spinal chordomas with regards to pathogenesis and treatments. Method Three terms – ‘spine’, ‘chordoma’ and ‘genomics’ were searched on PubMed and Embase. Papers published until 2022 were included. Exclusion criteria were conference s, letters, and duplicates. The final result was nineteen papers on PubMed, which were analysed in this review. Data collected were discussed under the respective subtopics. Results From the nineteen papers, the published evidence surrounding the genomics of spinal chordomas with respect to molecular pathogenesis and treatment modalities were collected and analysed. Brachyury and microRNAs (miRNAs) are two of the more significant molecular markers related to chordomas. Other molecular aberrations include chromosomal instability, long non-coding RNAs (lncRNAs), Sonic Hedgehog (Shh), as well as modifications in genome, exome, transcriptome, and proteome. Apart from surgical management, which is usually the gold standard approach to chordomas, genomic findings in chordomas have led to advancements in targeted therapy and immunotherapy. The integration of hyperthermia into radiotherapy could also be a potential novel therapy. Conclusions To date, great advancements have been made around the genomics of chordomas, but these are not specific to spinal chordomas. As such, apart from improving on the respective knowledge gaps identified in this review, studies focusing specifically on spinal chordomas would also be recommended.